Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

POINT Biopharma Global Yönetim

Yönetim kriter kontrolleri 4/4

POINT Biopharma Global's CEO'su Joe McCann, Jan2020 tarihinde atandı, in görev süresi 3.92 yıldır. in toplam yıllık tazminatı $ 2.84M olup, şirket hissesi ve opsiyonları dahil olmak üzere 16.9% maaş ve 83.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 3.28% ine doğrudan sahiptir ve bu hisseler $ 43.70M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.5 yıl ve 3 yıldır.

Anahtar bilgiler

Joe McCann

İcra Kurulu Başkanı

US$2.8m

Toplam tazminat

CEO maaş yüzdesi	16.9%
CEO görev süresi	3.9yrs
CEO sahipliği	3.3%
Yönetim ortalama görev süresi	2.5yrs
Yönetim Kurulu ortalama görev süresi	3yrs

Son yönetim güncellemeleri

Recent updates

POINT Biopharma Global Inc. (NASDAQ:PNT) Analysts Just Slashed This Year's Estimates

Aug 20

We Think POINT Biopharma Global (NASDAQ:PNT) Can Easily Afford To Drive Business Growth

Feb 01

CEO Tazminat Analizi

Joe McCann'un ücretlendirmesi POINT Biopharma Global'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2023	n/a	n/a	US$97m
Jun 30 2023	n/a	n/a	US$97m
Mar 31 2023	n/a	n/a	US$98m
Dec 31 2022	US$3m	US$480k	US$98m
Sep 30 2022	n/a	n/a	-US$79m
Jun 30 2022	n/a	n/a	-US$72m
Mar 31 2022	n/a	n/a	-US$56m
Dec 31 2021	US$740k	US$392k	-US$46m
Sep 30 2021	n/a	n/a	-US$37m
Jun 30 2021	n/a	n/a	-US$23m
Mar 31 2021	n/a	n/a	-US$18m
Dec 31 2020	US$282k	US$218k	-US$13m

Tazminat ve Piyasa: Joe 'nin toplam tazminatı ($USD 2.84M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 5.54M ).

Tazminat ve Kazançlar: Joe 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Joe McCann (45 yo)

3.9yrs

Görev süresi

US$2,839,772

Tazminat

Dr. Joe McCann, Ph.D. is Chief Executive Officer at POINT Biopharma Global Inc. since January 2020 and has been its Director since September 2019. Dr. McCann has overall responsibility for the day-to-day o...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Allan Silber	Executive Chairman	4.3yrs	US$2.57m	8.19% $ 109.1m
Joe McCann	CEO & Director	3.9yrs	US$2.84m	3.28% $ 43.7m
Neil Fleshner	Chief Medical Officer & Director	3.9yrs	US$598.69k	2.82% $ 37.6m
Jessica Jensen	Executive Vice President of Clinical Development	3.3yrs	US$1.87m	0% $ 0
Bill Demers	CFO & Corporate Secretary	3.3yrs	US$703.01k	Veri yok
Justyna Kelly	Chief Operating Officer	2yrs	Veri yok	Veri yok
Jazz Braich	SVP of People & Culture	less than a year	Veri yok	Veri yok
Ari Shomair	VP of Corporate Affairs & Chief of Staff	no data	Veri yok	Veri yok
Myra Herle	Executive Vice President of Regulatory Affairs	2.5yrs	Veri yok	Veri yok
Matthew Vincent	Senior Vice President of Business Development	1.9yrs	Veri yok	Veri yok
Chris Horvath	Executive VP of Commercial	1.5yrs	Veri yok	Veri yok
Valerie Hergott	Senior Vice President of Chemistry Manufacturing & Controls	less than a year	Veri yok	Veri yok

2.5yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: PNT 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Allan Silber	Executive Chairman	4.3yrs	US$2.57m	8.19% $ 109.1m
Joe McCann	CEO & Director	4.3yrs	US$2.84m	3.28% $ 43.7m
Neil Fleshner	Chief Medical Officer & Director	4.3yrs	US$598.69k	2.82% $ 37.6m
David Lubner	Independent Director	3.6yrs	US$176.85k	0.037% $ 487.6k
Yael Margolin	Independent Director	2.5yrs	US$170.00k	0.0016% $ 21.3k
Gerald Hogue	Independent Director	3yrs	US$184.35k	0.020% $ 269.9k
Jonathan Goodman	Lead Independent Director	3yrs	US$210.24k	0.039% $ 523.4k
Rajesh Malik	Independent Director	2.5yrs	US$170.00k	0.0035% $ 46.2k
Bridget Martell	Director	less than a year	Veri yok	Veri yok

3.0yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: PNT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3 yıldır).

POINT Biopharma Global Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new directors

Point Biopharma Global Inc. Appoints Bridget Martell to Its Board of Directors

Independent Director exercised options to buy US$122k worth of stock.

Executive Chairman recently bought US$311k worth of stock

High number of new directors

POINT Biopharma Announces Appointment of Chris Horvath as Executive Vice President, Commercial

Recent updates

POINT Biopharma Global Inc. Files Form 15

POINT Biopharma Global Inc.(NasdaqCM:PNT) dropped from S&P Biotechnology Select Industry Index

POINT Biopharma Global Inc.(NasdaqCM:PNT) dropped from NASDAQ Composite Index

Eli Lilly and Company (NYSE:LLY) completed the acquisition of POINT Biopharma Global Inc. (NasdaqCM:PNT) from Joe A. McCann, Allan Charles Silber, Neil E. Fleshner and others.

POINT Biopharma Global to be Delisted from the Nasdaq Capital Market Following the Consummation of the Merger

Price target decreased by 19% to US$13.85

Lantheus Holdings, Inc. and POINT Biopharma Global Inc. Announce Positive Topline Results from Pivotal Splash Trial in Metastatic Castration-Resistant Prostate Cancer

Consensus revenue estimates increase by 24%

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire POINT Biopharma Global Inc. (NasdaqCM:PNT) from Joe A. McCann, Allan Charles Silber, Neil E. Fleshner and others for approximately $1.4 billion.

New major risk - Share price stability

Price target decreased by 9.2% to US$15.44

Investor sentiment improves as stock rises 81%

Consensus revenue estimates fall by 54%

POINT Biopharma Global Inc. (NASDAQ:PNT) Analysts Just Slashed This Year's Estimates

High number of new directors

POINT Biopharma Global Inc. Expands Its Research with Next-Generation Isotopes, Publishing New Preclinical Data at SNMMI's Annual Congress

Point Biopharma Global Inc. Appoints Bridget Martell to Its Board of Directors

Consensus EPS estimates upgraded to US$0.80 loss

POINT Biopharma Announces FRONTIER Trial-in-Progress Poster Presentation at ASCO

Price target increased by 7.3% to US$16.90

Investor sentiment improves as stock rises 20%

Investor sentiment improves as stock rises 18%

Independent Director exercised options to buy US$122k worth of stock.

Forecast to breakeven in 2024

We Think POINT Biopharma Global (NASDAQ:PNT) Can Easily Afford To Drive Business Growth

Point Biopharma Completes Randomization in PNT2002’s Phase 3 Splash Trial

POINT Biopharma Global Inc. Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with Immunotherapy

Executive Chairman recently bought US$311k worth of stock

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Price target decreased to US$19.00

High number of new directors

POINT Biopharma Publishes Preclinical Data for Actinium-Labelled PNT2001, A Next-Generation PSMA Ligand, At EANM's Annual Congress

A Look At The Fair Value Of POINT Biopharma Global Inc. (NASDAQ:PNT)

Point Biopharma plummets on announcing common stock offering

Price target increased to US$21.00

POINT Biopharma Global GAAP EPS of -$0.27 misses by $0.05

POINT Biopharma Announces Appointment of Chris Horvath as Executive Vice President, Commercial

Chief Medical Officer & Director recently sold US$4.2m worth of stock

POINT Biopharma Global Inc. Unveils FRONTIER: A Pan-Cancer Fap-A Targeted Clinical Program

POINT Biopharma Global Inc. Confirms No Supply Shortages of 177Lu-PNT2002 for the Splash Trial

High number of new and inexperienced directors

POINT Biopharma Global Announces First Patient in European Union (EU) Dosed in the Phase 3 Splash Trial

POINT Biopharma Announces Abstract Publication of Dosimetry Data Findings from the Lead-In Cohort of the SPLASH Trial in mCRPC at the 2022 SNMMI Mid-Winter & ACNM Annual Meeting

POINT Biopharma Global Inc., Annual General Meeting, Jun 02, 2022

High number of new and inexperienced directors

POINT Biopharma Global Inc. Releases New Data and Exercises Option for Best-In-Class FAP Inhibitor

POINT Biopharma Global Inc. Announces Initiation of Randomization for Its Phase 3 SPLASH study Evaluating PNT2002 for mCRPC

POINT Biopharma Announces Early Completion of Enrollment and Initial Dosing in the Lead-In of Its Phase 3 SPLASH Study of PNT2002 for mCRPC

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş